Page 56 - Haematologica - Vol. 105 n. 6 - June 2020

A. Bazarbachi et al.
leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res. 2001;61(19):7233-7239.
27. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372-4380.
28. Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplica- tion in the tyrosine kinase domain-1 is asso- ciated with resistance to chemotherapy and inferior outcome. Blood. 2009;114(12):2386- 2392.
29. Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem dupli- cations in patients with acute myeloid leukemia. Blood. 2007;110(4):1262-1270.
30. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associ- ated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111(3):1552-1559.
31. Moreno I, Martin G, Bolufer P, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 muta- tions in acute myeloid leukemia. Haematologica. 2003;88(1):19-24.
32. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3- TKD mutations in AML: the combination matters--an analysis of 3082 patients. Blood. 2008;111(5):2527-2537.
33. Voso MT, Larson RA, Prior T, et al. Ratify (Alliance 10603): prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diag- nosed acute myeloid leukemia (AML) treat- ed with midostaurin or placebo plus stan- dard chemotherapy. Blood. 2018;132 (Suppl 1):2668.
34. Boddu P, Kantarjian H, Borthakur G, et al. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prog- nostic AML group. Blood Adv. 2017;1 (19):1546-1550.
35. Perry M, Bertoli S, Rocher C, et al. FLT3- TKD mutations associated with NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(12): e545-e550.
36. Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol. 2019;10:2040620719827310.
37. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464.
38. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728-1740.
39. Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a mul- ticentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984- 997.
40. Wang ES, Tallman MS, Stone RM, et al. Low relapse rate in younger patients ≤ 60 years
old with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) treated with crenolanib and cytarabine/anthracycline chemotherapy. Blood. 2017;130(Suppl 1):566.
41. Rollig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to stan- dard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicen- tre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691-1699.
42. Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemothera- py in elderly patients with acute myeloid leukemia: results from a randomized, place- bo-controlled trial. J Clin Oncol. 2013;31 (25):3110-3118.
43. Antar A, Otrock ZK, El-Cheikh J, et al. Inhibition of FLT3 in AML: a focus on sorafenib. Bone Marrow Transplant. 2017;52(3):344-351.
44. Macdonald DA, Assouline SE, Brandwein J, et al. A phase I/II study of sorafenib in com- bination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leuk Lymphoma. 2013;54(4):760-766.
45. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011;96(1):62-68.
46. Metzelder SK, Schroeder T, Lubbert M, et al. Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer. 2017;86:233- 239.
47. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS- like tyrosine kinase 3-internal tandem dupli- cation status. J Clin Oncol. 2013;31(29): 3681-3687.
48. Levis MJ, Perl AE, Altman JK, et al. Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). J Clin Oncol. 2015;33(15_suppl):7003.
49. Leung AY, Man CH, Kwong YL. FLT3 inhibi- tion: a moving and evolving target in acute myeloid leukaemia. Leukemia. 2013;27(2): 260-268.
50. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126(3): 319-327.
51. Winkler J, Rech D, Kallert S, et al. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. Leuk Res. 2010;34(10):e270-272.
52. Sharma M, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011;17(12): 1874-1877.
53. Metzelder SK, Schroeder T, Finck A, et al. High activity of sorafenib in FLT3-ITD-posi- tive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012;26(11):2353- 2359.
54. Rautenberg C, Nachtkamp K, Dienst A, et al. Sorafenib and azacitidine as salvage ther-
apy for relapse of FLT3-ITD mutated AML after allo-SCT. Eur J Haematol. 2017;98(4): 348-354.
55. Bazarbachi A, Labopin M, Battipaglia G, et al. Sorafenib improves survival of FLT3- mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of EBMT Acute Leukemia Working Party. Haematologica. 2019;104(9):e398- e401.
56. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655-4662.
57. Sid S, Rey J, Charbonnier A, et al. Treatment of post-transplant relapse of FLT3-ITD mutated AML using 5-azacytidine and sorafenib bitherapy. Clin Lymphoma Myeloma Leuk. 2017;17(4):241-242.
58. Sasaki K, Kantarjian HM, Kadia T, et al. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplica- tion mutation-positive acute myeloid leukemia. Cancer. 2019;125(21):3755-3766.
59. Yalniz F, Abou Dalle I, Kantarjian H, et al. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemother- apy with/without sorafenib. Am J Hematol. 2019;94(9):984-991.
60. Battipaglia G, Ruggeri A, Massoud R, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer. 2017;123(15): 2867-2874.
61. Chen YB, Li S, Lane AA, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20(12):2 042-2048.
62. Brunner AM, Li S, Fathi AT, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016;175(3):496-504.
63. Bazarbachi A, Labopin M, Battipaglia G, et al. Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia: in vivo T-cell depletion and posttransplant sorafenib maintenance improve survival. A retrospective acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. Clin Hematol Int. 2019;1(1):58-74.
64. Burchert A. Sorafenib As Maintenance ther- apy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-con- trolled multicentre sormain trial. Blood. 2018;132(Suppl 1):661.
65. Battipaglia G, Massoud R, Ahmed SO, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 mutated acute myeloid leukemia: an update. Clin Lymphoma Myeloma Leuk. 2019;19(8):506- 508.
66. Bornhauser M, Illmer T, Schaich M, et al. Improved outcome after stem-cell transplan- tation in FLT3/ITD-positive AML. Blood. 2007;109(5):2264-2265; author reply 2265.
67. Gale RE, Hills R, Kottaridis PD, et al. No evi- dence that FLT3 status should be considered
1514
haematologica | 2020; 105(6)